Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Nov 5;116(45):22429-22431.
doi: 10.1073/pnas.1916581116. Epub 2019 Oct 29.

Epigenetic targeting of DNA repair in lung cancer

Benjamin H Lok  1   2   3   4 , Charles M Rudin  5   6   7
Affiliations
Comment

Epigenetic targeting of DNA repair in lung cancer

Benjamin H Lok et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interest statement: C.M.R. has consulted regarding cancer drug development with AbbVie, Amgen, Ascentage, Bicycle, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Loxo, and PharmaMar, and serves on the SAB of Bridge Medicines and Harpoon Therapeutics.

Comment on

References

    1. Siegel R. L., Miller K. D., Jemal A., Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019). - PubMed
    1. Canadian Cancer Statistics Advisory Committee , Canadian Cancer Statistics 2019 (Canadian Cancer Society, 2019).
    1. Antonia S. J., et al. ; PACIFIC Investigators , Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342–2350 (2018). - PubMed
    1. Bradley J. D., et al. , Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol. 16, 187–199 (2015). - PMC - PubMed
    1. Raben D., et al. , Patterns of disease progression with durvalumab in stage III non-small cell lung cancer (PACIFIC). Intl. J. Rad. Oncol. Biol. Phys. 105, 683 (2019).

Publication types